Solve FSHD
Overview
Solve FSHD is a venture philanthropic organization that makes strategic investments in academic, biotech, and biopharmaceutical organizations to accelerate the development of therapies for Facioscapulohumeral muscular dystrophy (FSHD).
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Epicrispr Biotechnologies | Mar 2025 | Series B | - |
| Altay Therapeutics | Jul 2023 | Grant | Co-investor |
| miRecule, Inc. | Sep 2022 | Grant | Lead |
| Armatus Bio | May 2025 | VC Round | Lead |
| Ani Biome | May 2025 | Grant | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Solve FSHD based?
Solve FSHD is headquartered in Vancouver, British Columbia, Canada.
When was Solve FSHD founded?
Solve FSHD was founded in 2022.
How many portfolio companies does Solve FSHD have?
Solve FSHD has 6 portfolio companies in Caplight's dataset.
What are some companies in Solve FSHD's portfolio?
Portfolio companies visible on Caplight include Epicrispr Biotechnologies, Altay Therapeutics, miRecule, Inc., Armatus Bio, Ani Biome.
What was Solve FSHD's most recent investment shown here?
Solve FSHD's most recent investment in this portfolio sample was in Ani Biome in 2025.
What sectors does Solve FSHD focus on?
Solve FSHD focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Consumer & Commerce.
What company stages does Solve FSHD focus on?
Solve FSHD typically invests at the Mid stage.
What is Solve FSHD's AUM?
Solve FSHD's assets under management are estimated between $100.0M and $100.0M.